Sensorion Implements Reverse Share Split, Exchanging 50 Existing Shares for One New Share

French biotech firm Sensorion has announced a reverse share split, exchanging 50 existing shares for every 1 new share, according to AP News. The new shares will carry a par value of €5 each. The move is designed to reduce the total number of shares in circulation without changing the company's overall share capital.
Sensorion trades on the Euronext Growth Paris exchange under the ticker ALSEN, with ISIN code FR0012596468. The company focuses on developing therapies to restore and prevent hearing loss, Market Screener reported.
A reverse share split reduces the number of a company's shares while raising the price of each one. In this case, every 50 Sensorion shares become just 1 new share. The total value held by each shareholder stays the same. Think of it like exchanging 50 one-cent coins for one 50-cent coin — the amount of money does not change.
Crucially, the company's total share capital is not affected by this move, according to Market Screener. Only the number of shares and their individual price change. This is a common tool companies use to lift a low share price and meet stock exchange listing requirements.
One technical detail stands out in Sensorion's announcement. The company will waive the reverse split of a portion of its own treasury shares. This is done to make sure the exchange ratio of 50-to-1 produces a whole number of new shares. Without this step, fractional shares could result, which complicates record-keeping and shareholder payouts, Voice of Alexandria noted.
The final number of new shares is not entirely fixed. Sensorion noted that the total could be adjusted if holders of rights or other securities that convert into shares choose to act outside a specific suspension period. These instruments — such as warrants or convertible bonds — give their holders the right to get company shares at a set price.
If those holders exercise their rights during the suspension window, the adjustment would not apply. But any activity outside that window could change the final share count, Market Screener reported. This gives Sensorion some flexibility as it manages the transition to its new share structure.
Small biotech companies like Sensorion often trade at very low share prices while they work to bring new drugs to market. A reverse split can push the price per share higher, helping the company meet minimum price thresholds set by stock exchanges. Falling below those thresholds can trigger a delisting warning.
Sensorion is focused on hearing loss — a large and underserved medical field. The company has several therapies in development. Maintaining a healthy share price helps it stay visible to investors and keep access to future fundraising, according to Voice of Alexandria.
Publishers
4
Articles
4
Reach
4